Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?.

Prostate cancer and prostatic diseases

ElShafei A, DeWitt-Foy M, Calaway A, Fernstrum AJ, Hijaz A, Muncey W, Alfahmy A, Mahran A, Mishra K, Stephen Jones J, Polascik TJ.
PMID: 33483626
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):507-513. doi: 10.1038/s41391-020-00306-z. Epub 2021 Jan 22.

BACKGROUND: To assess whether prior interventional treatment for benign prostatic hyperplasia (BPH) influences oncologic or functional outcomes following primary whole-gland prostate cryoablation.METHODS: Among 3831 men with prostate cancer who underwent primary whole-gland prostate cryoablation, we identified 160 with a...

Cite
ElShafei A, DeWitt-Foy M, Calaway A, et al. Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?. Prostate Cancer Prostatic Dis. 2021;24(2):507-513doi: 10.1038/s41391-020-00306-z.
ElShafei, A., DeWitt-Foy, M., Calaway, A., Fernstrum, A. J., Hijaz, A., Muncey, W., Alfahmy, A., Mahran, A., Mishra, K., Stephen Jones, J., & Polascik, T. J. (2021). Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?. Prostate cancer and prostatic diseases, 24(2), 507-513. https://doi.org/10.1038/s41391-020-00306-z
ElShafei, Ahmed, et al. "Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?." Prostate cancer and prostatic diseases vol. 24,2 (2021): 507-513. doi: https://doi.org/10.1038/s41391-020-00306-z
ElShafei A, DeWitt-Foy M, Calaway A, Fernstrum AJ, Hijaz A, Muncey W, Alfahmy A, Mahran A, Mishra K, Stephen Jones J, Polascik TJ. Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):507-513. doi: 10.1038/s41391-020-00306-z. Epub 2021 Jan 22. PMID: 33483626.
Copy Download .nbib Format: NLM
Optimized Icariin Phytosomes Exhibit Enhanced Cytotoxicity and Apoptosis-Inducing Activities in Ovarian Cancer Cells.

Pharmaceutics

Alhakamy NA, A Fahmy U, Badr-Eldin SM, Ahmed OAA, Asfour HZ, Aldawsari HM, Algandaby MM, Eid BG, Abdel-Naim AB, Awan ZA, K Alruwaili N, Mohamed AI.
PMID: 32290412
Pharmaceutics. 2020 Apr 11;12(4). doi: 10.3390/pharmaceutics12040346.

Icariin (ICA) is a flavonol glycoside that has pleiotropic pharmacological actions. It has cytotoxic effects against ovarian cancer cells and increases their chemosensitivity to chemotherapeutic drugs. Phytosomes are identified for their potential in drug delivery of cytotoxic agents. Thus,...

Cite
Alhakamy NA, A Fahmy U, Badr-Eldin SM, et al. Optimized Icariin Phytosomes Exhibit Enhanced Cytotoxicity and Apoptosis-Inducing Activities in Ovarian Cancer Cells. Pharmaceutics. 2020;12(4)doi: 10.3390/pharmaceutics12040346.
Alhakamy, N. A., A Fahmy, U., Badr-Eldin, S. M., Ahmed, O. A. A., Asfour, H. Z., Aldawsari, H. M., Algandaby, M. M., Eid, B. G., Abdel-Naim, A. B., Awan, Z. A., K Alruwaili, N., & Mohamed, A. I. (2020). Optimized Icariin Phytosomes Exhibit Enhanced Cytotoxicity and Apoptosis-Inducing Activities in Ovarian Cancer Cells. Pharmaceutics, 12(4), . https://doi.org/10.3390/pharmaceutics12040346
Alhakamy, Nabil A, et al. "Optimized Icariin Phytosomes Exhibit Enhanced Cytotoxicity and Apoptosis-Inducing Activities in Ovarian Cancer Cells." Pharmaceutics vol. 12,4 (2020). doi: https://doi.org/10.3390/pharmaceutics12040346
Alhakamy NA, A Fahmy U, Badr-Eldin SM, Ahmed OAA, Asfour HZ, Aldawsari HM, Algandaby MM, Eid BG, Abdel-Naim AB, Awan ZA, K Alruwaili N, Mohamed AI. Optimized Icariin Phytosomes Exhibit Enhanced Cytotoxicity and Apoptosis-Inducing Activities in Ovarian Cancer Cells. Pharmaceutics. 2020 Apr 11;12(4). doi: 10.3390/pharmaceutics12040346. PMID: 32290412; PMCID: PMC7238269.
Copy Download .nbib Format: NLM
Formulation Design, Statistical Optimization, and In Vitro Evaluation of a Naringenin Nanoemulsion to Enhance Apoptotic Activity in A549 Lung Cancer Cells.

Pharmaceuticals (Basel, Switzerland)

Md S, Alhakamy NA, Aldawsari HM, Husain M, Kotta S, Abdullah ST, A Fahmy U, Alfaleh MA, Asfour HZ.
PMID: 32679917
Pharmaceuticals (Basel). 2020 Jul 15;13(7). doi: 10.3390/ph13070152.

Naringenin (NAR), a flavonoid mainly found in citrus and grapefruits, has proven anti-cancer activities. However, the poor water solubility and low bioavailability of NAR limits its use as a therapeutic agent. The aim of this study was to develop...

Cite
Md S, Alhakamy NA, Aldawsari HM, et al. Formulation Design, Statistical Optimization, and In Vitro Evaluation of a Naringenin Nanoemulsion to Enhance Apoptotic Activity in A549 Lung Cancer Cells. Pharmaceuticals (Basel). 2020;13(7)doi: 10.3390/ph13070152.
Md, S., Alhakamy, N. A., Aldawsari, H. M., Husain, M., Kotta, S., Abdullah, S. T., A Fahmy, U., Alfaleh, M. A., & Asfour, H. Z. (2020). Formulation Design, Statistical Optimization, and In Vitro Evaluation of a Naringenin Nanoemulsion to Enhance Apoptotic Activity in A549 Lung Cancer Cells. Pharmaceuticals (Basel, Switzerland), 13(7), . https://doi.org/10.3390/ph13070152
Md, Shadab, et al. "Formulation Design, Statistical Optimization, and In Vitro Evaluation of a Naringenin Nanoemulsion to Enhance Apoptotic Activity in A549 Lung Cancer Cells." Pharmaceuticals (Basel, Switzerland) vol. 13,7 (2020). doi: https://doi.org/10.3390/ph13070152
Md S, Alhakamy NA, Aldawsari HM, Husain M, Kotta S, Abdullah ST, A Fahmy U, Alfaleh MA, Asfour HZ. Formulation Design, Statistical Optimization, and In Vitro Evaluation of a Naringenin Nanoemulsion to Enhance Apoptotic Activity in A549 Lung Cancer Cells. Pharmaceuticals (Basel). 2020 Jul 15;13(7). doi: 10.3390/ph13070152. PMID: 32679917; PMCID: PMC7407592.
Copy Download .nbib Format: NLM
Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation.

Pharmaceutical development and technology

El-Say KM, Ahmed TA, Badr-Eldin SM, Fahmy U, Aldawsari H, Ahmed OAA.
PMID: 25019166
Pharm Dev Technol. 2015 Dec;20(8):919-926. doi: 10.3109/10837450.2014.938859. Epub 2014 Jul 14.

OBJECTIVE: Detailed optimization process was carried out to enhance permeation parameters, and hence bioavailability, of simvastatin (SMV) transdermal films.METHODS: SMV solubility was investigated in various oils, surfactants and co-surfactants/co-solvents. Mixtures of the selected components were prepared to identify zone...

Cite
El-Say KM, Ahmed TA, Badr-Eldin SM, et al. Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation. Pharm Dev Technol. 2014;20(8):919-926doi: 10.3109/10837450.2014.938859.
El-Say, K. M., Ahmed, T. A., Badr-Eldin, S. M., Fahmy, U., Aldawsari, H., & Ahmed, O. A. A. (2015). Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation. Pharmaceutical development and technology, 20(8), 919-926. https://doi.org/10.3109/10837450.2014.938859
El-Say, Khalid M, et al. "Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation." Pharmaceutical development and technology vol. 20,8 (2015): 919-926. doi: https://doi.org/10.3109/10837450.2014.938859
El-Say KM, Ahmed TA, Badr-Eldin SM, Fahmy U, Aldawsari H, Ahmed OAA. Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation. Pharm Dev Technol. 2015 Dec;20(8):919-926. doi: 10.3109/10837450.2014.938859. Epub 2014 Jul 14. PMID: 25019166.
Copy Download .nbib Format: NLM
Thymoquinone-Loaded Soy-Phospholipid-Based Phytosomes Exhibit Anticancer Potential against Human Lung Cancer Cells.

Pharmaceutics

Alhakamy NA, Badr-Eldin SM, A Fahmy U, Alruwaili NK, Awan ZA, Caruso G, Alfaleh MA, Alaofi AL, Arif FO, Ahmed OAA, Alghaith AF.
PMID: 32806507
Pharmaceutics. 2020 Aug 12;12(8). doi: 10.3390/pharmaceutics12080761.

Thymoquinone (TQ), a natural polyphenol, has been associated with various pharmacological responses; however, low bioavailability of TQ limits its clinical application. Thus, a novel phytosomal delivery system of TQ-Phospholipon

Cite
Alhakamy NA, Badr-Eldin SM, A Fahmy U, et al. Thymoquinone-Loaded Soy-Phospholipid-Based Phytosomes Exhibit Anticancer Potential against Human Lung Cancer Cells. Pharmaceutics. 2020;12(8)doi: 10.3390/pharmaceutics12080761.
Alhakamy, N. A., Badr-Eldin, S. M., A Fahmy, U., Alruwaili, N. K., Awan, Z. A., Caruso, G., Alfaleh, M. A., Alaofi, A. L., Arif, F. O., Ahmed, O. A. A., & Alghaith, A. F. (2020). Thymoquinone-Loaded Soy-Phospholipid-Based Phytosomes Exhibit Anticancer Potential against Human Lung Cancer Cells. Pharmaceutics, 12(8), . https://doi.org/10.3390/pharmaceutics12080761
Alhakamy, Nabil A, et al. "Thymoquinone-Loaded Soy-Phospholipid-Based Phytosomes Exhibit Anticancer Potential against Human Lung Cancer Cells." Pharmaceutics vol. 12,8 (2020). doi: https://doi.org/10.3390/pharmaceutics12080761
Alhakamy NA, Badr-Eldin SM, A Fahmy U, Alruwaili NK, Awan ZA, Caruso G, Alfaleh MA, Alaofi AL, Arif FO, Ahmed OAA, Alghaith AF. Thymoquinone-Loaded Soy-Phospholipid-Based Phytosomes Exhibit Anticancer Potential against Human Lung Cancer Cells. Pharmaceutics. 2020 Aug 12;12(8). doi: 10.3390/pharmaceutics12080761. PMID: 32806507; PMCID: PMC7463966.
Copy Download .nbib Format: NLM
Opioid prescription patterns among urologists as compiled from within Medicare.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Callegari M, Jella T, Mahran A, Alfahmy A, Muncey W, Patel A, Loeb A, Thirumavalavan N.
PMID: 33999804
Can Urol Assoc J. 2021 Nov;15(11):E574-E581. doi: 10.5489/cuaj.7086.

INTRODUCTION: We aimed to evaluate opioid prescribing patterns of urologists across the United States (U.S.) and the District of Columbia (D.C.) using publicly available data from Medicare Part D. Our secondary analysis was to identify any loco-regional trends that...

Cite
Callegari M, Jella T, Mahran A, et al. Opioid prescription patterns among urologists as compiled from within Medicare. Can Urol Assoc J. 2021;15(11):E574-E581doi: 10.5489/cuaj.7086.
Callegari, M., Jella, T., Mahran, A., Alfahmy, A., Muncey, W., Patel, A., Loeb, A., & Thirumavalavan, N. (2021). Opioid prescription patterns among urologists as compiled from within Medicare. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 15(11), E574-E581. https://doi.org/10.5489/cuaj.7086
Callegari, Michael, et al. "Opioid prescription patterns among urologists as compiled from within Medicare." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 15,11 (2021): E574-E581. doi: https://doi.org/10.5489/cuaj.7086
Callegari M, Jella T, Mahran A, Alfahmy A, Muncey W, Patel A, Loeb A, Thirumavalavan N. Opioid prescription patterns among urologists as compiled from within Medicare. Can Urol Assoc J. 2021 Nov;15(11):E574-E581. doi: 10.5489/cuaj.7086. PMID: 33999804; PMCID: PMC8641906.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries